Optimization of dosing for EGFR-mutant non–small cell lung cancer with evolutionary cancer modeling J Chmielecki, J Foo, GR Oxnard, K Hutchinson, K Ohashi, R Somwar, ... Science translational medicine 3 (90), 90ra59-90ra59, 2011 | 598 | 2011 |
Evolution of acquired resistance to anti-cancer therapy J Foo, F Michor Journal of theoretical biology 355, 10-20, 2014 | 298 | 2014 |
The multi-element probabilistic collocation method (ME-PCM): Error analysis and applications J Foo, X Wan, GE Karniadakis Journal of Computational Physics 227 (22), 9572-9595, 2008 | 288 | 2008 |
Multi-element probabilistic collocation method in high dimensions J Foo, GE Karniadakis Journal of Computational Physics 229 (5), 1536-1557, 2010 | 259 | 2010 |
A physical sciences network characterization of non-tumorigenic and metastatic cells Scientific reports 3 (1), 1449, 2013 | 182 | 2013 |
Intratumor heterogeneity in evolutionary models of tumor progression R Durrett, J Foo, K Leder, J Mayberry, F Michor Genetics 188 (2), 461-477, 2011 | 156 | 2011 |
Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies J Foo, F Michor PLoS computational biology 5 (11), e1000557, 2009 | 142 | 2009 |
The impact of microenvironmental heterogeneity on the evolution of drug resistance in cancer cells SM Mumenthaler, J Foo, NC Choi, N Heise, K Leder, DB Agus, W Pao, ... Cancer informatics 14, CIN. S19338, 2015 | 108 | 2015 |
Evolution of resistance to anti-cancer therapy during general dosing schedules J Foo, F Michor Journal of theoretical biology 263 (2), 179-188, 2010 | 108 | 2010 |
Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer J Foo, J Chmielecki, W Pao, F Michor Journal of Thoracic Oncology 7 (10), 1583-1593, 2012 | 104 | 2012 |
Vortex mode selection of a rigid cylinder subject to VIV at low mass-damping D Lucor, J Foo, GE Karniadakis Journal of Fluids and Structures 20 (4), 483-503, 2005 | 98 | 2005 |
Dose-dependent differential mRNA target selection and regulation by let-7a-7f and miR-17-92 cluster microRNAs J Shu, Z Xia, L Li, ET Liang, N Slipek, D Shen, J Foo, S Subramanian, ... RNA biology 9 (10), 1275-1287, 2012 | 91 | 2012 |
Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib J Foo, MW Drummond, B Clarkson, T Holyoake, F Michor PLoS Computational Biology 5 (9), e1000503, 2009 | 82 | 2009 |
Stochastic dynamics of cancer initiation J Foo, K Leder, F Michor Physical biology 8 (1), 015002, 2011 | 78 | 2011 |
A high-content image-based method for quantitatively studying context-dependent cell population dynamics CM Garvey, E Spiller, D Lindsay, CT Chiang, NC Choi, DB Agus, ... Scientific reports 6 (1), 29752, 2016 | 71 | 2016 |
Fitness Conferred by BCR-ABL Kinase Domain Mutations Determines the Risk of Pre-Existing Resistance in Chronic Myeloid Leukemia K Leder, J Foo, B Skaggs, M Gorre, CL Sawyers, F Michor PloS one 6 (11), e27682, 2011 | 70 | 2011 |
Evolutionary dynamics of tumor progression with random fitness values R Durrett, J Foo, K Leder, J Mayberry, F Michor Theoretical population biology 78 (1), 54-66, 2010 | 69 | 2010 |
Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer SM Mumenthaler, J Foo, K Leder, NC Choi, DB Agus, W Pao, P Mallick, ... Molecular pharmaceutics 8 (6), 2069-2079, 2011 | 66 | 2011 |
Understanding the role of phenotypic switching in cancer drug resistance EB Gunnarsson, S De, K Leder, J Foo Journal of theoretical biology 490, 110162, 2020 | 59 | 2020 |
Comparison of cell and organoid-level analysis of patient-derived 3D organoids to evaluate tumor cell growth dynamics and drug response S Kim, S Choung, RX Sun, N Ung, N Hashemi, EJ Fong, R Lau, E Spiller, ... SLAS DISCOVERY: Advancing the Science of Drug Discovery 25 (7), 744-754, 2020 | 57 | 2020 |